Non-alcoholic Steatohepatitis Biomarkers Market by Biomarker Type (Apoptosis Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Serum Biomarkers) and End User (Academics and Research Institute, Diagnostic Laboratories, Pharma and CROs, and Hospitals) and Forecast 2017-2021

Non-alcoholic Steatohepatitis Biomarkers Market by Biomarker Type (Apoptosis Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Serum Biomarkers) and End User (Academics and Research Institute, Diagnostic Laboratories, Pharma and CROs, and Hospitals) and Forecast 2017-2021

Non-alcoholic Steatohepatitis or Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis (NASH) and irreversible liver damage (cirrhosis). Biomarkers offer a potential prognostic or diagnostic indicator for disease manifestation, progression or both. Serum biomarkers, including total cholesterol, triglycerides, insulin resistance and C-peptide, have been used for many years. Emerging biomarkers, such as apolipoprotein A1, apolipoprotein B, leptin, adiponectin, free fatty acids, ghrelin and tumour necrosis factor-alpha, have been proposed as tools that could provide valuable complementary information to that obtained from traditional biomarkers. Moreover, markers of cell death and mitochondrial dysfunction (cytokeratins) represent powerful predictors of risk. For biomarkers to be clinically useful in accurately diagnosing and treating disorders, age-specific reference intervals that account for differences in sex and ethnic origin are a necessity.

The global non-alcoholic steatohepatitis biomarkers market segmentation is based on biomarker type (apoptosis biomarkers, hepatic fibrosis biomarkers, oxidative stress biomarkers, serum biomarkers) and end user (academics and research institute, diagnostic laboratories, pharma and CROs, and hospitals).

The global non-alcoholic steatohepatitis biomarkers market report provides market size (Revenue US$ Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global non-alcoholic steatohepatitis biomarkers market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global non-alcoholic steatohepatitis biomarkers market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global non-alcoholic steatohepatitis biomarkers market and included in this report are BioPredictive S.A.S, Exalenz Biosciences Ltd., Genfit SA, One Way Liver S.L., Prometheus Laboratories Inc. (Nestle Health Sciences), Quest Diagnostics Incorporated, Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics), and Siemens Healthcare Private Ltd. (Siemens Healthineers).

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Products
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Product Type (cells, media, serum, vaccine, protein, instrument, etc.)
    • Source Type
    • Reagents and Consumables Type
    • Diagnostic Test
    • Indication Type
    • Technology
    • Diagnostics, Therapeutic or Surgical Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  8. Recommendations
  9. References

Non-alcoholic Steatohepatitis Biomarkers Market

1. Biomarker Type
1.1. Apoptosis Biomarkers
1.2. Hepatic Fibrosis Biomarkers
1.3. Oxidative Stress Biomarkers
1.4. Serum Biomarkers
1.5. Others

2. End User
2.1. Academics and Research Institutes
2.2. Diagnostic Laboratories
2.3. Hospitals
2.4. Pharma and CROs

3. Geography
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World

4. Company Profiles
4.1. BioPredictive S.A.S
4.2. Exalenz Biosciences Ltd.
4.3. Genfit SA
4.4. One Way Liver S.L.
4.5. Prometheus Laboratories Inc. (Nestle Health Sciences)
4.6. Quest Diagnostics Incorporated
4.7. Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics)
4.8. Siemens Healthcare Private Ltd. (Siemens Healthineers)

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*